Title: DIAGNOSIS OF SHWACHMAN-DIAMOND SYNDROME

Abstract: The SBDS gene has been identified as the site of mutations associated with SDS. Methods are provided for determining whether a subject is suffering from SDS.
For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
DIAGNOSIS OF SHWACHMAN-DIAMOND SYNDROME

Field of the Invention

The invention relates to methods for diagnosing and treating individuals with Shwachman-Diamond Syndrome and for detecting Shwachman-Diamond disease carriers. More specifically, the invention relates to the identification of the Shwachman-Bodian-Diamond Syndrome (SBDS) gene and the identification of mutations of this gene which are associated with Shwachman-Diamond Syndrome.

Background of the Invention

Shwachman-Diamond Syndrome (SDS [MIM 260400]) is an autosomal recessive disorder with clinical features including exocrine pancreatic insufficiency, haematological dysfunction, and skeletal abnormalities\textsuperscript{1,2,3}. Patients with SDS have a high risk of bone marrow failure and are at risk of developing acute myelogenous leukaemia (AML). SDS is the second most common cause of pancreatic insufficiency after cystic fibrosis and involves the failure of development of the exocrine pancreas. Other manifestations include skeletal abnormalities and liver function abnormalities, the latter being notable in young patients.

Many SDS patients present with malabsorption and steatorrhoea related to their pancreatic insufficiency. Many such children fail to thrive due to the malabsorption and also due to their disinclination to eat normally because of gastrointestinal upsets. The haematological dysfunction most consistently involves neutropenia but can also present as thrombocytopenia or pancytopenia. Serious consequences for SDS patients include recurring severe infections that can be life threatening if the diagnosis is not made with the provision of prompt treatments. Further, traditional methods for treatment of bone marrow failure are generally not successful in SDS patients at this time but the surveillance and monitoring of the bone marrow to determine the occurrence of myelodysplasia, aplastic anaemia and/or the development of AML do provide some options for intervention.
It is therefore important for the optimum development and overall long term prognosis of these children that they are diagnosed as having SDS as early as possible so that infections may be treated with appropriate interventions, so that blood and bone marrow can be monitored for cellularity (numbers and cell types) and so that pancreatic enzyme supplementation may be instituted to provide adequate or near normal food absorption.

There are other diseases associated with exocrine pancreatic dysfunction, such as Cystic Fibrosis and Pearson Marrow Syndrome, and other diseases such as congenital neutropenia, Blackfan-Diamond Syndrome and Fanconi Anaemia can mimic the haematological manifestations of SDS. It is important, for proper treatment, that SDS is diagnosed as early as possible but at present SDS can only be distinguished from other diseases causing similar symptoms by complex, symptom-based tests which may have to be repeated many times before a conclusion is reached (Rothbaum et al., (2002), J. Pediatrics, v. 141, pp. 266-270; Ginzberg et al., (2000), Am. J. Hum. Genet., v. 66, pp. 1413-1416).

There is therefore a real need for a convenient and definitive test, such as a genetic test or a gene product-based immunological test, to diagnose SDS. Further, as the bone marrow failure aspects are so serious, there is need to provide new options to correct the associated deficiencies. The identification and analysis of the gene that is affected in SDS would provide for such opportunities.

Segregation analysis of an international collection of families of SDS patients supports an autosomal recessive mode of inheritance (Ginzberg et al., (2000), Am. J. Hum. Genet., v. 66, pp. 1413-1416). Previous studies of families with SDS showed that the putative SDS locus mapped to the centromeric region of chromosome 7, to a 1.9 cM interval at 7q11.45. The genetic defect associated with the disease has, however, not previously been identified.

Summary of the Invention
The invention provides a convenient and rapid method for the diagnosis of SDS, based on the finding that SDS is associated with mutations in a previously uncharacterised gene residing within the 1.9 centiMorgan disease interval at 7q11 delineated by linkage and haplotype analysis in family studies. The gene, with a 1.6 kb transcript, was originally designated by the inventors as DEPCH and its encoded protein of 250 amino acids was designated depechin. The gene has been renamed as Shwachman-Bodian-Diamond Syndrome (SBDS) gene. A second copy previously designated DEPCHP and now designated SBDSP, with 97% nucleotide sequence identity, resides within a locally duplicated genomic block of at least 305 kb, and appears to be a pseudogene. Recurring mutations, the apparent result of recombination between the duplicated gene copies, were found in 89% of unrelated SDS patients (n=158), with 60% carrying two converted alleles and 29% having a different mutation in the second allele. The extent of the converted segments varied but consistently included at least one of two critical sequence changes predicted to result in truncation of the encoded protein. Other less common disease alleles involve missense and insertion/deletion changes distinct from those in the pseudogene. The gene is a member of a highly conserved protein family, with putative orthologues in diverse species ranging from archæabacteria to eukaryotes. The archæal orthologues are located within highly conserved operons that include homologues of genes involved in RNA processing, suggesting that SDS may be the result of a deficiency in some aspect of RNA metabolism that is essential for hæmatopoiesis, chondrogenesis and the development of the exocrine pancreas.

"SBDS or SBDS gene" is the chromosome 7q11.22 gene as described herein which when mutated is associated with SDS. This definition includes sequence polymorphisms wherein the nucleotide substitutions in the gene sequence do not affect the function of the gene product.

"SBDS protein" is the protein encoded by the SBDS gene.

"Mutant SBDS gene" is the SBDS gene containing one or more mutations which, if present on both alleles of the gene, lead to SDS.
In accordance with one embodiment, the invention provides a method for determining whether a subject is suffering from Schwachman-Diamond Syndrome (SDS) comprising

obtaining a nucleic acid sample from the subject, and
conducting an assay on the nucleic acid sample to determine the presence or absence of a SBDS gene mutation associated with SDS, wherein the presence of a SBDS gene mutation associated with SDS in both SBDS alleles indicates that the subject suffers from SDS.

In accordance with a further embodiment, the invention provides a method for determining whether a subject is an SDS carrier comprising

obtaining a nucleic acid sample from the subject, and
conducting an assay on the nucleic acid sample to determine the presence or absence of a SBDS gene mutation associated with SDS, wherein the presence of a SBDS gene mutation associated with SDS in one SBDS allele indicates that the subject is an SDS carrier.

In accordance with a further embodiment, the invention provides a method for determining whether a subject is suffering from Shwachman-Diamond Syndrome (SDS) comprising

obtaining a tissue sample from the subject, and
conducting an assay on the tissue sample to determine the level of SBDS protein in the sample, wherein a reduced level of SBDS protein in the sample relative to a control sample indicates that the subject suffers from SDS.

In accordance with a further embodiment, the invention provides a method for determining whether a subject is at risk for developing acute myelogenous leukaemia (AML) comprising

obtaining a nucleic acid sample from the subject, and
conducting an assay on the nucleic acid sample to determine the presence or absence of a SBDS gene mutation associated with SDS, wherein the presence of a SBDS gene mutation associated with SDS indicates that the subject is at risk for development of AML.
In accordance with a further embodiment, the invention provides a method for treating a subject suffering from SDS comprising administering to the subject a therapeutically effective amount of a substantially purified SBDS protein or of an isolated nucleotide sequence encoding an SBDS protein.

In accordance with a further embodiment, the invention provides an isolated nucleic acid molecule encoding an SBDS protein.

In accordance with a further embodiment, the invention provides an isolated nucleic acid molecule comprising at least about 10, 20, 30, 50, 75 or 100 consecutive nucleotides of SEQ ID NO:1 or 29.

In accordance with a further embodiment, the invention provides a substantially purified SBDS protein.

In accordance with a further embodiment, the invention provides an antibody which binds specifically to an epitope of an SDS protein.

In accordance with a further embodiment, the invention provides a nucleotide sequence selected from the group consisting of:

(a) 5'-GCGTAAAAAGCCACAATAC-3' (SEQ ID NO:3);
(b) 5'-CTATGACAGTATTCGTAAGACTAGG-3' (SEQ ID NO:4);
(c) 5'-GGGGATTTGTTGTGTCCTTGA-3' (SEQ ID NO:5);
(d) 5'-CTTTCCCTCCAGAAAAACACG-3' (SEQ ID NO:6);
(e) 5'-AAATGGTAAGGCAAATACGG-3' (SEQ ID NO:7);
(f) 5'-ACCAAAGTTTCTTTATTATTAGAAATGAC-3' (SEQ ID NO:8);
(g) 5'-GCTCAAACCATCATTACATATTGA-3' (SEQ ID NO:9);
(h) 5'-CACCAGGGCTCCATGCAGA-3' (SEQ ID NO:10);
(i) 5'-AAAGGGTCTTTTAAACACTTC-3' (SEQ ID NO:11);
(j) 5'-GAAATATCTCTGACGTTTACAACA-3' (SEQ ID NO:12);
(k) 5'-CCTCAGATGATGTAAGACACTA-3' (SEQ ID NO:13);
(l) 5'-CAACCTGACATTGGGCTTTGAC-3' (SEQ ID NO:14);
(m) 5'-GCTTCTGCTCCACCTGAC-3' (SEQ ID NO:15);
(n) 5'-AGCTATGCTGCAGCTTAC-3' (SEQ ID NO:16);
(o) 5'-ATGCATGTCCAAGTTTCAAG-3' (SEQ ID NO:17);
(p) 5'-CTCATGGCTATTTTTGATGA-3' (SEQ ID NO:18);
(q) 5'-TAAGCCTGCCAGACAC-3' (SEQ ID NO:19);
6
(r) 5'-CACTCTGGACTTTGACATCTT-3' (SEQ ID NO:20);
(s) 5'-TGGTTGTTTTCACCAGATA-3' (SEQ ID NO:21);
(t) 5'-AGATAAGAAAAGACACACACAACT-3' (SEQ ID NO:22);
(u) 5'-GAAATCGCTGCTACAA-3' (SEQ ID NO:23);
(v) 5'-TCAGCTTCTTGCTTCCAT-3' (SEQ ID NO:24);
(w) 5'-TAAGTAGGCTGAGCAGACA-3' (SEQ ID NO:25);
(x) 5'-CATCAAGGTCCTTTCTCAAG-3' (SEQ ID NO:26);
(y) 5'-CCTGTCTCTGCCCCAAAGTC-3' (SEQ ID NO:27); and
(z) 5'-AGGGAAACATTITCATAACTCA-3' (SEQ ID NO:28).

In accordance with a further embodiment, the invention provides a transgenic non-human mammal having within its genome an SBDS gene with at least one mutation associated with SDS.

In accordance with a further embodiment, the invention provides a kit comprising at least one pair of primers suitable for amplification of at least a portion of an SBDS gene.

Summary of Drawings

Fig. 1 shows an integrated map of the interval of chromosome 7 where the gene deficiency that leads to SDS resides. a, The refined map interval, flanked by microsatellite markers D7S2429 and D7S502, is shown with reference to the Genbridge 3 radiation hybrid panel. b, An expanded map of sub regions from RH bins 65 and 72 based on genomic sequences from BAC clones in GenBank. The regions contains at least 305 kb that has duplicated intrachromosomally. The positions and orientations of the paralogous duplicons along 7q were determined by unique STS content and radiation hybrid mapping. c, Identified genes in the BAC contigs are shown. Duplicon A contains at least 2 genes, SBDS and SDCR2A (Shwachman-Diamond Critical Region-2A). d, SBDS is composed of 5 exons (coding regions in grey, noncoding regions in black) spanning 7.9 kb of genomic sequence. The location of oligonucleotide primers used for mutation screening by genomic PCR and RT-PCR are indicated.
Fig. 2 shows mutations in SBDS associated with SDS. a, Map of SBDS (coding regions in light blue) and sequence alignment of the exon 2 region of SBDS and SBDSP, with gene-specific sequences in green and pseudogene sequences in red. In comparison to SBDS, SBDSP exon 2 contains sequence changes (underlined in red) that are predicted to result in truncation of its predicted protein product. These include an in-frame stop codon at 184 bp and a T>C change at 250+10 bp (corresponding to the invariant T of the donor splice site at 258+2 bp in SBDS) which results in the use of an alternate donor splice site (invariant splice site positions are boxed) at 250+1 bp. The sequence differences in SBDSP present restriction sites for Bsu36I, and Ddel at 183 bp and Cac8I at 240+7 bp. b, Electropherograms for cloned sequences from the exon 2 region of SBDS reveal sequence changes (red) derived from gene conversion events between SBDS and its pseudogene; three gene converted alleles are shown. These include [183TA>CT], [258+2T>C], and an extended conversion mutation [183TA>CT +201A>G +258+2T>C] with the intervening adenine (position 201) to guanine change. In each case, flanking sequences, including those at 129-2 bp and 258+124 bp, have not been converted (green). c, A restriction map of the SBDS exon 2 amplifier (primers E and F, Fig. 1d) showing the position of Cac8I (C) and Bsu36I (B) restriction sites. Square brackets indicate the positions of restriction sites corresponding to converted sequences. The pedigree of family SW20 is shown with affected individuals in black and carriers in grey. Restriction fragment analysis of PCR amplified SBDS exon 2 sequences revealed that the brothers inherited [183TA>CT] through the father and paternal grandfather, and [258+2T>C] through the mother and maternal grandmother. Patient P1 is heterozygous for [258+2T>C] and the extended conversion mutation ([183TA>CT +201A>G +258+2T>C]). Two unrelated control individuals are also shown (C1 and C2). d, Restriction maps of the gene and pseudogene loci showing the locations of all Ndel restriction sites (N). Hybridisation of a DNA probe derived from a partial SBDS cDNA (green) to genomic DNAs restriction digested with Ndel indicates that members of family SW6 (including patient P1 with two converted alleles) show a pattern of
hybridisation similar to two unrelated control individuals (C3 and C4) indicating that no rearrangements or deletions have occurred in the vicinity of SBDS or SBDSP. e, Sequence traces depicting other representative coding mutations in patient SBDS compared to controls (N), including an insertion ([96_97insA]), a deletion ([119delG]) and two missense mutations ([24C>A] and [505C>T]).

Fig. 3 shows expression analysis of SBDS and SBDSP. FTh Fetal thymus, FS Fetal spleen, FLi Fetal Liver, FK Fetal kidney, FSM Fetal skeletal muscle, FLu Fetal lung, FH Fetal heart, FB Fetal brain, K Kidney, SM Skeletal muscle, Lu Lung, H Heart, B Brain, Li Liver, Pl Placenta, Pa Pancreas, Th Thymus, Sp Spleen, Ly Lymphocytes, To Tonsil, BM Bone Marrow, Le Peripheral Blood Leukocytes, LN Lymph Node, GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase. a, RNA expression survey of SBDS and SBDSP in primary tissues using a cloned RT-PCR product containing the entire SBDS open reading frame (primers T and R). Cumulative levels of both gene and pseudogene transcripts appear to be lower in thymus and bone marrow. An alternatively spliced product was detected in several tissues and was most prominent in peripheral blood leukocytes (Le). As shown in the lane indicated with an asterisk, this large transcript was detected with a probe derived from intron 1. b, Analysis of patient EBV-transformed B lymphoblastoid-derived RNA shows that SBDS and SBDSP cumulative expression is lower in some patients compared to a control individual (C). The probe used to provide a control for RNA loading consisted of a 983bp cloned cDNA fragment from glyceraldehyde 3-phosphate dehydrogenase (GAPDH). c, RT-PCR expression analysis of SBDS and SBDSP was carried out with specific oligonucleotide primers and indicated that both transcripts are widely expressed. Sequencing of PCR products led to the identification of an exon 2\textsuperscript{\textminus} transcript. RT-PCR indicated that the alternatively spliced product (shown as 349bp) is present in all tissues tested, however its expression is significantly lower than transcripts that include exon 2 (shown as 479bp).

Fig. 4 shows CLUSTALX alignment of SBDS-encoded protein, SBDS, and representative orthologues. Strong conservation is seen throughout the
alignment from archaebacteria to complex eukaryotes. ‘**’ represents absolutely conserved residues in the alignment, ‘:’ represents positions at which conservative amino acid substitutions are observed and ‘.’ represents semi conservative substitutions. The degree of sequence similarity is less pronounced towards the C-terminus although subgroups retain strong conservation. The human amino acid sequence (Hsa) is shown in bold. The locations of all identified coding mutations are represented as white letters on a black background and corresponding amino acid sequence changes are shown above the alignment. A putative U1-like zinc finger domain in three plant orthologues is indicated with a black bar. Ath Arabidopsis thaliana, Dme Drosophila melanogaster, Cel Caenorhabditis elegans, Mmu Mus musculus, Hsa Homo sapiens, Ola Oryzias latipes, Sce Saccharomyces cerevisiae, Ecu Encephalitozoon cuniculi, Mac Methanosarcina acetivorans str. C2A, Hnr Halobacterium sp. NRC-1, Mka Methanopyrus kandleri str. AV19, Mja Methanococcus jannaschii, Afu Archaeoglobus fulgidus, Pab Pyrococcus abyssi, Tac Thermoplasma acidophilum, Pae Pyrolobus aerophilum, Sso Sulfolobus solfataricus, Ape Aeropyrum pernix, Pba Populus balsamifera, Gar Gossypium arboreum, *derived from partial GenBank EST sequence.

Fig. 5 shows the SBDS cDNA and its predicted encoded polypeptide. A: The nucleotide sequence of the cDNA corresponding to SBDS mRNA is shown numbered with the +1 starting at the first nucleotide, A, of the translation initiating codon. The 5' and 3' untranslated regions are shown in lower case, and the coding segment is shown in upper case text. B: amino acid sequence of the encoded polypeptide of 250 amino acids is shown numbered.

Fig. 6 shows the aligned genomic sequence for the human SBDS gene (SBDS) and its pseudogene SBDSP (SBDSP) and for the mouse SBDS gene (MUSBDS). The sequences for the five human exons are included with numbering that corresponds to that indicated in Fig. 5A. SBDS specific oligonucleotide primers that can be used to determine the nucleotide sequence of expressed RNA or of each of the exons for mutation detection are indicated by underlining of the SBDS sequence. Dual specific
oligonucleotide primers are indicated by the underlining of both SBDS and SBDSP sequences. The sequence of oligonucleotide primers indicated in the forward direction (the arrows pointing to the right) correspond directly to the sequence shown, while those primers in the reverse direction (the arrows pointing to the left) are comprised of the reverse complement of the indicated sequence.

Figure 7 shows the specificity and reactivity of antibodies produced to detect the SBDS protein. a, Polyclonal antibodies produced with recombinant SBDS (anti-rSBDS), left panel or a carboxyl peptide (anti-CpSBDS) of amino acids 224-239 (aa224IKKETKKGKSLEVNL239) of SBDS, right panel, detected single bands of the predicted size in whole cell extracts of induced host E. coli BL21 containing the pET-28a expression vector with an in-frame fusion of the entire SBDS open reading frame. A polyclonal antibody to an amino peptide (anti-NpSBDS) of amino acids 32-47 (aa32CYKNKVGVWRSGVEKD47) of SBDS has also been generated, data not shown. b, The anti-rSBDS antibody also detected SBDS expressed transiently in HEK293 cells under the control of a CMV promoter. The bands corresponds to those detected by anti-Myc or anti-HA antibodies. The subtle shifts in sizes are due to the various epitope tags and/or their locations that have been fused in frame to the SBDS gene, including amino or carboxyl positioned Myc (N-Myc or C-Myc) N-HA or amino or carboxyl positioned HA (N-HA or C-HA) tags. c, Anti-rSBDS also detected a prominent band in whole cell extracts of the predicted size for SBDS in BxPC3 (ATCC CRL-1687), SV40-transformed human fibroblasts (GM00639), Caco-2 (ATCC HTB-37), AR42J (ATCC CRL-1492), EBV transformed human lymphoblast (GM003798), PANC1 (ATCC CRL-1469) and J.RT3 (ATCC TIB-153) cell lines. The total protein loaded per extract is as indicated below each panel.

**Detailed Description of the Invention**

The inventors have identified the SBDS gene and described the association of mutations in that gene with the autosomal recessive disease, SDS.
Clinical presentation in SDS can be variable but family studies have supported a single gene locus near the centromere at 7q11\textsuperscript{2,4,5}. Eighteen positional candidate genes were identified in compiled genomic sequences from the locus, and eight of these were analysed for mutations in members of linked families. Disease-associated changes were identified in a gene represented by the full length, 1.6 kb cDNA clone flj10917 (OVARC1000321). The gene was initially designated by the inventors as DEPCH (\textit{Development of Exocrine Pancreas, Chondrocytes and Haematological lineages}). The gene has been renamed (as approved by the Human Genome Organisation Gene Nomenclature Committee) as Shwachman-Bodian-Diamond Syndrome (SBDS) gene. The cDNA sequence is given in Fig. 5A (SEQ ID NO:1). SBDS is composed of 5 exons spanning 7.9 kb, and is contained in BAC clone RP11-325K1. The nucleotide sequences of the exons and surrounding introns are given in Fig. 6. The sequence of murine SBDS is also shown in Fig. 6. SBDS and part of an adjacent gene reside in a block of genomic sequence of at least 305 kb that is locally duplicated (Fig. 1). The paralogous duplcon was mapped distally, and contains an unprocessed pseudogene copy of SBDS, named SBDSP. The pseudogene transcript is 97\% identical to the SBDS transcript with small deletions and single nucleotide changes that clearly disrupt coding potential.

The protein product encoded by SBDS, termed SBDS, is a member of a highly conserved protein family (Pfam UPF00023)\textsuperscript{20}. Orthologues exist in species ranging from archaebacteria to vertebrates and plants (Fig. 4). The sequence of 250 amino acids is given in Fig. 5B (SEQ ID NO:2) for a predicted polypeptide of 28.8kDa with a pl of 8.9. The predicted amino acid sequence has no homology to any known functional domain, and no signal peptides were detected. The \textit{S. cerevisiae} orthologue, encoded by ORF YLR022c, has been found to bind specifically and with high affinity to the phospholipids PI(4,5)P2 and PI(4)P using yeast proteome chips\textsuperscript{21}. The gene has also been deleted by the Yeast ORF Deletion Project and haploid spores lacking YRL022c were found to be inviable\textsuperscript{22}. Indirect lines of evidence suggest that orthologues of SBDS may play a role in RNA metabolism. First,
YLR022c has been clustered with other genes encoding RNA processing enzymes based on microarray expression profile analysis. In addition, SBDS archael orthologues are located in conserved operons that contain several RNA processing genes, including homologues of subunits of the eukaryotic exosome and RNaseP complexes. The A. thaliana orthologue, along with sequences derived from partial cDNAs from P. balsamifera and G. arboreum, have extended carboxyl termini corresponding to putative RNA-binding domains, suggesting a functionally relevant fusion in flowering plants (Fig. 4). These observations suggest that SDS may be the result of a defect in an RNA processing pathway. Manifestation of disease must reflect the loss or perturbation of a cellular function that is particularly critical for the development of pancreatic acini, myeloid lineages, and chondrocytes at growth plates of bones. The associated symptoms and the complications due to bone marrow failure may reflect not only the loss of one gene but also pleiotropic consequences of an aberrant pathway.

Sequence changes that do not alter protein-associated activities and that occur in normal individuals are likely to correspond to gene polymorphisms. A current accepted standard to discriminate polymorphisms from mutations is to screen 100 individuals of comparable ethnic background that are not affected with SDS. Examples of polymorphisms detected in SBDS are given in Table 2. SDS-associated mutations are shown in Table 1.

**Diagnostic Methods**

The invention provides a diagnostic method for determining whether a subject, such as a human subject, suffers from, or is at risk of developing, symptoms of SDS. In one embodiment, the method involves examining a nucleic acid sample from the subject for the presence or absence of a mutation of the SBDS gene associated with SDS. Such mutations include 183_184TA→CT; 183_184TA→CT+258+2T→C; 258+2T→C; 24C→A; 96-97insA; 119 delG; 131A→G; 199A→G; 258+1G→C; 260T→G; 291-293delTAAinsAGTTCAAGTATC; 377G→C; 505C→T; 56G→A; 93C→G; 97A→G; 101A→T; 123delC; 279_284delTCAACT; 296_299delAAGA;
354A→C; 428C→T+443A→G; 458A→G; 460-1G→A; 506G→C; and
624+1G→C. These mutations are identified in relation to the numbering of
the nucleotide sequence of SEQ ID NO:1.

Many methods known to those of skill in the art can be used to detect
the presence or absence of a SBDS gene mutation in the subject's nucleic
acid.

The cDNA sequence of the wild type SBDS gene is shown in Figure 5
and is available at GenBank Accession Number AY169963 (NM_016038).
The exon structure and flanking intron sequences are shown in Figure 6.

"Mutations" of the wild type SBDS gene associated with SDS include
conversions, deletions, insertions, inversions or point mutations, either in the
coding regions of the gene or gene regulatory regions.

A number of types of assay may be used to determine whether a
subject has an SBDS gene mutation associated with SDS, including, for
example, sequencing exons or other portions of the gene, including regulatory
or intronic segments, PCR-RFLP analysis, allele specific PCR, allele specific
oligonucleotide hybridisation restriction fragment length polymorphism (RFLP)
analysis.

Where a direct sequencing assay is used, the sample may be DNA or
RNA, for example genomic DNA or mRNA. Gene-controlling DNA segments
and exons of an individual can be amplified and then examined for direct
sequence changes, or scanned with methods that detect a heterozygous state
followed by sequencing. These latter scanning methods can include single
stranded conformational analysis (Orita M, Iwahana H, Kanazawa H, Hayashi
K and Sekiya T (1989), "Detections of polymorphisms of human DNA by gel
Acad. Sci, USA 86: 2776-2770), denaturing gradient gel electrophoresis
(Wartell RM, Hosseini SH and Moran CP Jr (1990), "Detecting base pair
substitutions in DNA fragments by temperature-gradient gel electrophoresis",
(Nucleic Acids Res. 18: 2699-2705; Sheffield VC, Cox DR, Lerman LS and
Myers RM (1989) or "Attachment of a 40-base-pair G + C rich sequence (GC
clamp) to genomic DNA fragments by the polymerase chain reaction results in
improved detection of single-base changes" (Proc. Natl. Acad. Sci, USA 86: 232-236); and denaturing high pressure liquid chromatography Cotton RGH, Edkins E, Forrest S (eds) 1998 "Mutation detection: a Practical Approach" IRL Press, Oxford, and heteroduplex analysis Keen J, Lester D, Inglehearn C, Curtis A, Bhattacharya S (1991) Rapid detection of single base mismatches as heteroduplexes on Hydrolink gels. Trends Genet., 7:5, amongst other methods. Larger deletions or insertions can be detected by traditional Southern blot analysis of DNA digest with restriction enzymes (Southern EM. (1975) 'Detection of specific sequences among DNA fragments separated by gel electrophoresis', J Mol Biol 98:503-17). Mutant alleles can be distinguished by observing their inheritance from each parent and although each patient will have two affected alleles, they will typically appear in heterozygous state (all of the references of this paragraph are incorporated herein by reference).

The diagnostic methods of the invention are used to screen subjects showing symptoms of possible SDS, such as pancreatic insufficiency to identify SDS, or to screen relatives of known SDS cases to determine whether they may be at risk of developing SDS symptoms.

The diagnostic method of the invention should preferably be carried out on samples from children at a young age in order to establish the diagnosis and allow appropriate treatment. The diagnostic method may also be used as a prenatal test, using amniotic fluid or CVS samples.

With respect to determining carrier status, as discussed below, the test may be carried out at any age, preferably at an age greater than 16 years in relatives of SDS patients.

Signs of SDS generally are evident in children at an early age and the diagnostic methods of the invention will usually be employed to determine if a child presenting with SDS symptoms is indeed suffering from SDS. On occasion, a sibling or close relative may be screened to determine if he or she suffers from SDS.

Suitable samples for testing of nucleic acid include buccal swabs, blood samples and bone marrow aspirates.
In one embodiment, genomic DNA is extracted from the sample and a target portion of the genomic DNA comprising the SBDS gene or a selected portion thereof is amplified by a polymerase chain reaction using suitable oligonucleotide primers, such as those described herein. The amplified nucleic acid is then sequenced using conventional techniques. The sequence is compared with the wild type sequence to determine the presence or absence of SDS-associated mutations. Primers must be selected which will amplify only the SBDS gene and not the pseudogene, as shown in Figure 6. Since a larger number of SDS-associated mutations have been observed in exon 2 of SBDS gene, it is preferable to look first for mutations in that exon. If no mutations are found in exon 2, exons 1 and 3 to 5 are similarly examined in turn.

One of skill in the art can select suitable primers by reference to the SBDS sequence of Figure 6, suitable primers are also identified in Example 1. Preferred primer pairs for amplification of SBDS exons are as follows:

Exon 1: A & B or Q & B;
Exon 2: E & F;
Exon 3: G & H;
Exon 4: SDCR9x4seqB;
(5' - GCCTTCACCTCTCCTCAGT - 3') & J; and
Exon 5: SDCR9x5Fseq
(5' - GCTTGCCCTCAAAGGAAGTTT - 3') & L.

Regulatory regions of SBDS, such as the promoter region, may also be examined using suitable primers.

Promoter primers include SDCR9prom1RA (5' - CAGCCGACGACCTGGTTTT - 3') and SDCR9prom6FA (5' - GTGCCAACGCTGTTTTTTT - 3').

These primers amplify a 501 bp segment partially overlapping exon 1, which likely contains the major controlling elements for the transcription of SBDS mRNA.

For conversion mutations found in exon 2, examination of the test subject's parents can be used to distinguish whether the subject has two
conversion recombinations rather than one extended conversion recombination.

In a further embodiment of the invention, an RNA sample is obtained from the test subject and is reverse transcribed by conventional methods to give a corresponding cDNA which is amplified by PCR and sequenced.

In a further embodiment, RFLP analysis may be used to detect SBDS gene mutations. Such methods of analysis are well known to those of skill in the art and an example is described in the Examples herein and in reference 30. Test samples are compared with normal controls and samples from patients with known mutations.

In a further embodiment, analysis of SBDS expression or of the level of SBDS protein may be used to determine whether a subject suffers from or is at risk of SDS. As described herein, SBDS is expressed in a wide variety of tissues, including the most disease-relevant tissues, pancreas, bone marrow and myeloid cell lineages. A blood or tissue sample may therefore be used to evaluate SBDS expression or SBDS protein level. As seen in Figure 3b, mRNA level is notably reduced in SDS patients. SBDS expression can be evaluated by many routine methods, for example by mRNA analysis as described in the Examples herein and in reference 30.

In a further embodiment, an antibody specific for SBDS protein and carrying a detectable label can be used to assess the level of SBDS protein in a tissue sample of a subject by an immunological technique. Many suitable techniques, such as immunoprecipitation or ELISA assays, are known to those of skill in the art and are described, for example, in "Using antibodies - a laboratory manual", (1999), Harlow et al., Cold Spring Harbor Lab. Press. The level of protein in a test subject is compared with that in similar tissue samples from unaffected individuals, a reduction in level of SBDS protein being indicative of SDS. The identification of the SBDS gene and the absence of any known closely related homologues enables the preparation of antibodies highly specific for SBDS protein.

**Detection of SDS Carriers**
The invention further provides a method for determining whether a subject is an SDS carrier by determining whether the subject has an SDS-associated mutation in one allele of the SBDS gene.

The methods described above for detecting an SDS-associated mutation in a sample from a subject suspected of suffering from SDS may also be applied to detect carriers of the disease. The described methods for detecting such mutations in a nucleic acid sample from a subject are preferred.

Screening for SDS carriers is carried out especially on members of families with known SDS cases and may be important for genetic counselling of such family members regarding their likelihood of passing the disease on to their children. Generally, a method would be used to look for a specific mutation already found in an affected family member.

Identification of Further Mutations

The present invention also enables the identification of additional SDS-associated mutations of the SBDS gene, for example by examining SDS patients using the methods and primers described herein.

Amplification of target portions of the gene, followed by direct nucleic acid sequencing, as described herein for diagnostic purposes, and comparison with the wild type sequence, may be used to identify additional SDS-associated mutations.

Alternatively, assessment of the expression level of the SBDS gene, as described herein, may indicate reduced expression levels and point to further mutations which can be characterised by nucleic acid analysis as described above.

Nucleic Acids

The invention provides SBDS nucleic acids and homologues and portions thereof. Preferred nucleic acids have a nucleotide sequence which is at least 80%, preferably at least 90% and more preferably more than 97%
homologous to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:29 or to a complement thereof.

Preferred nucleic acids are mammalian and especially preferred are human nucleic acids. Nucleic acids of the invention include nucleic acids encoding an amino acid sequence with at least 75%, preferably at least 90% and more preferably at least 99% amino acid identity to the amino acid sequence of SEQ ID NO:2, and nucleic acids encoding a portion of such amino acid sequences.

Also within the scope of the invention are nucleic acid molecules useful as probes or primers and comprising at least about 10, 20, 30, 50, 75, 90 or 100 consecutive nucleotides of SEQ ID NO:1.

Also within the scope of the invention are nucleic acids which hybridise under stringent conditions to a nucleic acid of the nucleotide sequence SEQ ID NO:1 or to a complement or a portion thereof. Stringent conditions for nucleic acid hybridisation are known to those skilled in the art and are described, for example, in "Protocols in Molecular Biology", (1989), John Wiley & Sons, N.Y., at 6.3.1 to 6.3.6.

Also within the scope of the invention are nucleic acids which differ from the sequence of SEQ ID NO:1 due to the degeneracy of the genetic code.

**Proteins**

The invention provides substantially purified SBDS proteins and portions thereof. These proteins and portions thereof are useful for the preparation of antibodies specific for SBDS proteins.

"Substantially purified" as used herein with respect to proteins means a protein preparation which is at least 75%, more preferably at least 90% and most preferably at least 99% by weight of SBDS protein.

Preferred SBDS proteins have an amino acid sequence which is at least about 75%, preferably at least about 90% and more preferably at least about 99% identical to the amino acid sequence of SEQ ID NO:2.
In a preferred embodiment, the SBDS protein has the amino acid sequence of SEQ ID NO:2. Full length proteins and portions thereof corresponding to one or more domains thereof or comprising at least 5, 10, 25, 50, 75 or 100 consecutive amino acids of SEQ ID NO:2 are within the scope of the invention.

The proteins and peptides of the invention may be isolated and purified by conventional protein purification methods such as gel-filtration chromatography, ion exchange chromatography, high performance liquid chromatography, immunoprecipitation or immunoaffinity purification.

SBDS proteins may be prepared by conventional recombinant methods, for example using the cDNAs described herein (for example human sequence has Genbank Accession Number AY169963) or a selected portion thereof. Since the SBDS gene is small, native gene expression may be achieved with the incorporation of natural promoter and enhancer gene elements. Suitable vectors and host cells for such expression are well known to those of skill in the art.

The expressed protein can be purified by standard procedures, as described above.

**Antibodies**

The present invention also enables the preparation of antibodies or antibody fragments which bind specifically to SBDS protein or to a portion thereof.

The term “antibody” means a monoclonal antibody or a polyclonal antibody, which binds specifically to a particular peptide, polypeptide or epitope, i.e. with greater affinity than to other peptides, polypeptides or epitopes, and includes chimeric antibodies, humanised antibodies and single chain antibodies.

Chimeric antibodies are antibodies which contain portions of antibodies from different species. For example, a chimeric antibody may have a human constant region and a variable region from another species. Chimeric antibodies may be produced by well known recombinant methods, as
described in U.S. Patents Nos. 5,354,847 and 5,500,362, and in the scientific literature (Couto et al., 1993), Hybridoma, 12:485-489).

Humanised antibodies are antibodies in which only the complementarity determining regions, which are responsible for antigen binding and specificity, are from a non-human source, while substantially all of the remainder of the antibody molecule is human. Humanised antibodies and their preparation are also well known in the art – see, for example, U.S. Patents Nos. 5,225,539; 5,585,089; 5,693,761 and 5,693,762.

Single chain antibodies are polypeptide sequences that are capable of specifically binding a peptide or epitope, where the single chain antibody is derived from either the light or heavy chain of a monoclonal or polyclonal antibody. Single chain antibodies include polypeptides derived from humanised, chimeric or fully-human antibodies where the single chain antibody is derived from either the light or heavy chain thereof.

The term “antibody fragment” means a portion of an antibody that displays the specific binding of the parent antibody and includes Fab, F (ab')2 and Fv fragments.

**Polyclonal Antibodies**

In order to prepare polyclonal antibodies, purified SBDS protein may be obtained, for example, as described herein. The purified protein or a portion thereof, coupled, if desired, to a carrier protein such as bovine serum albumin or keyhole limpet hemocyanin, as in Cruikshank WW, Center DM, Nisar N, Wu M, Natke B, Theodore AC, and Kornfeld H., (1994), Proc. Natl. Acad. Sci. USA 24: 5109-5113, is mixed with Freund’s adjuvant and injected into rabbits or other suitable laboratory animals.

Following booster injections at weekly intervals, the rabbits or other laboratory animals are then bled and the sera isolated. The sera can be used directly or purified prior to use by various methods including affinity chromatography employing Protein A-Sepharose, antigen Sepharose or Anti-mouse-Ig-Sepharose. Further purification methods well known in the art may be utilised to remove viral and/or endotoxin contaminants.
Monoclonal Antibodies

As will be understood by those skilled in the art, monoclonal antibodies may also be produced using an SBDS protein or a portion thereof. The protein or portion thereof, coupled to a carrier protein if desired, is injected in Freund's adjuvant into mice. After being injected three times over a three-week period, the mice spleens are removed and resuspended in phosphate buffered saline (PBS). The spleen cells serve as a source of lymphocytes, some of which are producing antibody of the appropriate specificity. These are then fused with a permanently growing myeloma partner cell, and the products of the fusion are plated into a number of tissue culture wells in the presence of a selective agent such as HAT. The wells are then screened by ELISA to identify those containing cells making binding antibody. These are then plated and after a period of growth, these wells are again screened to identify antibody-producing cells. Several cloning procedures are carried out until over 90% of the wells contain single clones which are positive for antibody production. From this procedure a stable line of clones which produce the antibody is established. The monoclonal antibody can then be purified by affinity chromatography using Protein A Sepharose, ion-exchange chromatography, as well as variations and combinations of these techniques. Truncated versions of monoclonal antibodies may also be produced by recombinant techniques in which plasmids are generated which express the desired monoclonal antibody fragment in a suitable host.

In a further embodiment, a cell line is provided which secretes an antibody specific for an SBDS protein or a portion thereof; a cell line secreting an antibody specific for a human SBDS protein is preferred.

Diagnosis of Predisposition to AML

A number of SDS patients have been found to develop AML. It is of some concern that individuals who have survived into adulthood without being diagnosed as SDS sufferers, because of minimal or unrecognised symptoms, may nevertheless also be at risk for the development of AML. The present
invention permits the identification of these individuals as SDS sufferers, so that they may be monitored for early signs of AML and appropriately treated. Although widespread screening of the population may not be practical, screening of relatives of diagnosed SDS patients for SDS-associated mutations is completely feasible, as also would be screening individuals exhibiting early or more overt signs of bone marrow transformation.

In addition, SDS carriers, who have an SDS-associated mutation in only one allele of the SBDS gene and are therefore asymptomatic, may be at risk for AML if they should experience loss or mutation of the wild-type allele, particularly in haematological tissues. Again, screening of family members in SDS-affected families will indicate such genetic changes.

**Kits**

The invention further provides kits for use in the diagnostic methods described above for determining whether a subject is suffering from or is at risk for SDS, for determining whether a subject is a carrier of SDS or for determining whether a subject is at risk for AML. Such kits can comprise, for example, one or more pairs of oligonucleotide primers suitable for amplification of the SBDS gene or portions thereof, such as primers suitable for amplification of particular exons of SBDS, particularly human SBDS, as described for example in Figure 6. such kits can also contain instructions for use of the primers, and optionally, additional reagents required for the diagnostic methods described herein.

**Therapeutic Methods**

The invention further provides methods and compositions for treating subjects, including humans, suffering from SDS.

Methods of treatment are directed to restoring normal SBDS function in the subject.
Such methods include gene therapy to restore normal function at the gene level and administration of normal SBDS protein or portions thereof to make up for lack of normal gene expression.

Gene therapy may, for example, involve administration to the subject of a construct comprising an expression vector containing a nucleotide sequence encoding a wild type SBDS protein. Suitable expression vectors include retroviral, adenoviral and vaccinia virus vectors. Administration may be intravenous, oral, subcutaneous, intramuscular or intraperitoneal.


The organ with the most serious life threatening consequences, the bone marrow, may be treated by ex vivo gene therapy. This would involve the 1) extraction of bone marrow cells, 2) introduction of cDNA without mutations in conjunction with expression guiding elements followed by 3) re-introduction of these modified cells back to the bone marrow. Similar strategies have been used successfully in other diseases including severe combined immunodeficiency -X1 (M Cavazzana-Calvo, S Halcein-Bey, G de Saint Basile, F Gross, E Yvon, P Nusbaum, F Selz, C Hue, S Certain, J-L Casanova, P Bousso, F Le Deist and A Fischer. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672; all of which are incorporated herein by reference). The SBDS gene is notably small such that native gene expression may be achieved with the incorporation of natural promoter and enhancer gene elements.

The SBDS nucleotide sequences described herein may be used in conventional expression systems, as described herein, to permit production of depechin protein in amounts sufficient for antibody production or for therapy.

Therapeutic compositions in accordance with the invention comprise an isolated nucleotide sequence encoding an SBDS protein or effective fragment thereof or a substantially purified SBDS protein or effective fragment thereof.

Transgenic animal models of SDS

The invention further enables the creation of an animal model of SDS which is important for further study of how SBDS mutations lead to the various SDS-associated disease manifestations and for testing of potential
therapeutics. A number of non-human mammals may be used to create such a model, including without limitation mice, rats, rabbits, sheep, goats and non-human primates. An animal model of SDS may have within its genome one or both SBDS genes with at least one mutation which when expressed results in symptoms of SDS. Identification and sequencing of the mouse SBDS gene homologue, as described herein, facilitates the creation of such animal models, for example a mouse model.

Methods for the creation of transgenic animals are well known to those of skill in the art. A transgenic animal according to the invention is an animal having cells that contain a transgene which was introduced into the animal or an ancestor of the animal at a prenatal (embryonic) stage. A transgenic animal can be created, for example, by introducing the gene of interest into the male pronucleus of a fertilised oocyte by, e.g., microinjection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The gene of interest may include appropriate promoter sequences, as well as intronic sequences and polyadenylation signal sequences. Methods for producing transgenic animals are disclosed in, e.g., U.S. Pat. Nos. 4,736,866 and 4,870,009 and Hogan et al., A Laboratory Manual, Cold Spring Harbor Laboratory, 1986. A transgenic founder animal can be used to breed additional animals carrying the transgene. A transgenic animal carrying one transgene can also be bred to another transgenic animal carrying a second transgene to create a "double transgenic" animal carrying two transgenes. Alternatively, two transgenes can be co-microinjected to produce a double transgenic animal. Animals carrying more than two transgenes are also possible. Furthermore, heterozygous transgenic animals, i.e., animals carrying one copy of a transgene, can be bred to a second animal heterozygous for the same transgene to produce homozygous animals carrying two copies of the transgene. For a review of techniques that can be used to generate and assess transgenic animals, skilled artisans can consult Gordon (Intl. Rev. Cytol., 115:171-229 (1989)), and may obtain additional guidance from, for example: Hogan et al, Manipulating the Mouse Embryo (Cold Spring Harbor Press, Cold Spring Harbor, N.Y. 1986); Krimpenfort et

EXAMPLES

The examples are described for the purposes of illustration and are not intended to limit the scope of the invention.

Methods of molecular biology, genetics, protein and peptide biochemistry and immunology referred to but not explicitly described in this disclosure and examples are reported in the scientific literature and are well known to those skilled in the art.

Methods

Human Subjects. Families with SDS included in this study have been described, and additional families have been obtained through ongoing recruitment\(^2\). The criterion for inclusion in the study was the presence of both exocrine pancreatic dysfunction and haematologic abnormalities, including neutropenia and other problems associated with bone marrow failure. Consent was obtained from all participating families, and procedural approval was obtained from the human subjects review board of The Hospital for Sick Children, Toronto (HSC). Genomic DNA was extracted either from Epstein-Barr virus (EBV) transformed B-lymphoblastoid cell lines or directly from peripheral white blood cell pellets, as described by Miller et al.\(^24\). Patient and control RNA was extracted from EBV-transformed B-lymphoblastoid cell lines as previously described\(^25\). DNA from 100 control Caucasian individuals (Human variation panel HD100CAU) was purchased from Coriell Cell Repositories (Camden, NJ).
Physical Mapping. Genomic sequences were identified through BLAST analysis of STSs and genetic markers in the SDS critical interval against the GenBank non-redundant (nr) and high throughput genome sequence (htgs) databases\(^9\). Where the density of pre-existing markers was low, BAC and YAC clones assigned to the region were subcloned and sequenced to provide new STSs as described\(^5\). Genomic sequences were compiled manually and the framework was supported by radiation hybrid mapping of select STSs.

Candidate Gene Identification. Candidate genes were identified in genomic sequences through the use of annotation data provided by GenBank (http://www.ncbi.nlm.nih.gov) and Project Ensembl (http://www.ensembl.org)\(^{26,27}\). \textit{Ab initio} gene predictions were obtained through the use of GeneScript. Human genomic sequences were also compared to mouse genomic sequences (available through Celera Discovery System and Celera Genomics’ associated databases) from the syntenic interval on mouse chromosome 5 using PipMaker2 to identify regions of cross-species conservation\(^{28}\). All \textit{in silico} gene predictions were confirmed by RT-PCR analysis using random-primed cDNA derived from fetal brain, and/or testes poly(A)+ mRNA (Clontech, Palo Alto, CA).

Mutation Detection. The genomic structure of the \textit{SBDS} gene and its pseudogene copy were used to design primer pairs using Primer3 to screen coding regions\(^{29}\). The position of primer pairs is shown (Figs. 1 and 6). PCR products were directly sequenced or cloned using a Topo TA-cloning kit (Clontech) prior to sequencing. Primer pairs (specific for \textit{SBDS} unless otherwise stated) used were: A (5'-GGGTAAAAGCCACAATAC-3') and B (5'-CTACAGTCTATCCGTAAGACTAG-3') (exon 1), C (5'-GGGGATTTGTGTGTTCTTG-3') and D (5'-CTTTTCTCCAGAAAAACAG-3') (exon 2, \textit{SBDS/SBDS} dual-specific), E (5'-AAATGGTAAAGGCAAATACGG-3') and F (5'-ACCAAGTTCTTTATTATTGAAGTGAC-3') (exon 2), G (5'-GCTCAACTTACATATTGA-3') and H (5'-CACTTGCTCCATGCAGA-3') (exon 3), I (5'-
AAAGGGTCATTATAACACTTC-3') and J (5'-
GAAAATATCTGACGTTTACAACA-3') (exon 4), K (5'-
TCCACTGTAGATGTGAACTAACTC-3') and L (5'-
CACTCCTGAGCTTTCATCTCT-3') (exon 5), M (5'-
GCTTCTGCTCCACCTGAC-3') and N (5'AGCTATGCTGCAGCTGTTAC-3')
(exons 1 & 2, SBDS/SBDS dual-specific), O (5'-
ATGCATGCTCAAGTTTCAAG-3') and P (5'-TCCATGGCTATATTGTGATGA-
3') (exons 2 & 3, SBDS/SBDS dual-specific). Patients were also screened
for mutations through sequencing of RT-PCR products from random-primed
cDNA derived from patient EBV-transformed B-lymphoblastoid cell lines.
Primers used were: Q (5'-TAAGCCTGCCACACACAC-3') and R (5'-
CACTCTGGACTTTCATCTT-3') (yields full length SBDS open reading
frame), Q and S (5'-TGTTGGTTTTCACCAGAATA-3'), and T (5'-
AGATAAAGAAAGACACACACAAG-3) and R. Gene conversion mutations
were detected through restriction analysis of exon 2 PCR fragments. Exon 2
was amplified from patient DNA using PCR primers C & D or E & F, and
purified using a MinElute PCR Cleanup Kit (Qiagen). Restriction digestion
using Ddel (not shown) or Bsu036l ([183TA>CT]) and Cac8l ([258+2T>C])
(New England Biolabs, Beverly, MA) was carried out as recommended by the
manufacturer and analyzed by agarose gel electrophoresis. For all mutations,
allele-specific oligonucleotide hybridisation to amplified SBDS exons from
control individuals was carried out as described30.

**Southern Hybridisation.** Genomic DNA from patients and control individuals
was subjected to restriction digestion with Ndel (New England Biolabs) as
recommended by the manufacturer and products were separated by agarose
gel electrophoresis. The DNA was blotted and hybridised with a radiolabeled
SBDS partial cDNA probe (exons 1-3) as described30.

**RT-PCR and RNA Blot Analysis.** A panel of cDNAs derived from 22 adult
and fetal tissues (Clontech) were analyzed by RT-PCR according the
supplier's recommendations. Primers used were T and R (SBDS), and (5'-
TAAGTAAGCCTGCCAGACA-3') and (5'-CATCAAGGTTTTTCCAAG-3') (SBDSP). Primers used to assess the relative amount of SBDS exon 2 alternative splicing were U (5'-GAAATCGCCTGCTACAAA-3') and V (5'-TCAGCTTCTGCTTTCAT-3'). RNA blots of poly(A)+ mRNA (Clontech) were hybridized to DNA probes labeled with [α\(^{32}\)P]-dCTP. The SBDS probe was a cloned RT-PCR fragment (primers Q and R). The intron 1 probe was PCR amplified from genomic DNA using primers (5'-CCTGCTCTGCCCCAAGTCTC-3') and (5'-AGGGAACACATTTCAAAACCTCA-3').

**Sequence Alignment and Analysis.** SBDS orthologues were identified through BLASTP analysis of amino acid sequences in the GenBank nr database, and through TBLASTN analysis of the GenBank EST database (dbEST). Sequences were aligned with CLUSTALX using default parameters followed by manual adjustment. Amino acids were analysed for the presence of functional motifs using Pfam and associated databases (http://www.sanger.ac.uk/Software/Pfam/).

**Genbank Accession Numbers.** SBDS consensus cDNA, AY169963 cDNA flj10917, AK001779; SDCR2A (cDNA flj10900), AK001762; SDCR3 (cDNA flj10099), AK000961; BAC RP11-458F8, AC073335; BAC RP11-325K1, AC079920; BAC RP11-584N20, AC069291; BAC RP11-324F21, AC073089; BAC RP11-166O4, AC006480; BAC RP11-479C13, AC005236. Depechin orthologues: Arabidopsis thaliana At1g43860 gene product, NP_564488; Drosophila melanogaster CG8549 gene product, NP_648057; Caenorhabditis elegans protein W06E11.4.p, NP_497226; Mus musculus protein 22A3, P70122; Oryzias latipes amino acid sequence derived from cDNA clone MF01SSA157A09 5' and 3' overlapping sequence reads, BJ013200 and BJ025159; Saccharomyces cerevisiae Ylr022cp, NP_013122; Encephalitozoon cuniculi ECU08_1610 gene product, NP_597289; Methanosarcina acetivorans str. C2A MA1778 gene product, NP_616704; Halobacterium sp. NRC-1 Vng1276c, NP_280149; Methanopyrus kandleri str. AV19 MK0384 gene product, NP_613669; Methanococcus jannaschii MJ0592.
gene product, NP_247572; Archaeoglobus fulgidus AF0491 gene product, NP_069327; Pyrococcus abyssi PAB0418 gene product NP_126299; Thermoplasma acidophilum Ta1291m gene product, NP_394745; Pyrobaculum aerophilum PAE2209 gene product, NP_559847; Sulfolobus solfataricus SSO0737 gene product, NP_342243; Aeropyrum pernix APE1167 gene product, NP_147753; Populus balsamifera subsp. Trichocarpa amino acid sequence derived from cDNA clone F038P45Y, BI121507; Gossypium arboreum amino acid sequence derived from cDNA clone GA__Ed0050B07f, BQ402534.

**Example 1**

RT-PCR analysis of several SDS patients with SBDS-specific oligonucleotide primers (indicated as RT-PCR primers Q and R in Fig. 1a and described in Fig. 6) revealed recurring sequence changes in exon 2, including a TA>CT dinucleotide change at position 183 or an 8 bp deletion at the end of the exon (the nucleotide numbering is described in Figs. 5 and 6). Analysis of SBDS genomic sequences confirmed the presence of the [183TA>CT] sequence change and revealed a [258+2T>C] nucleotide change in patients expressing the deleted SBDS transcript. [258+2T>C] is predicted to disrupt the donor splice site of intron 2, and the 8 bp deletion observed in the transcript is consistent with use of an upstream cryptic splice donor site at position 251. Alignment of patient SBDS sequences to genomic sequences from GenBank and control individuals indicated that both changes corresponded to sequences normally present in SBDSP (Fig. 2a, b). The dinucleotide alteration [183TA>CT] introduces an in-frame stop codon (K62X) while [258+2T>C] and its resultant 8 bp deletion also causes premature truncation of the encoded protein by frameshift (84Cfs3). Patient alleles were also identified that contain both of these changes together with an additional silent nucleotide change ([J201A>G]) in the intervening segment, again consistent with the pseudogene sequence (Fig. 2b). The [183TA>CT] and [258+2T>C] changes could be detected in amplified SBDS genomic DNA followed by restriction digestion with Bsu36I and Cac8I, respectively (Fig. 2a,
c) Analysis of SDS pedigrees revealed that these changes were inherited and disease-associated. An example of segregating alleles in a linked pedigree is shown in Fig 2c. The specificity of genomic DNA amplimers for SBDS was supported by the absence of additional pseudogene-like sequence changes in nucleotide positions flanking the 183 and 258+2 bp positions (Fig. 2b) and the absence of any SBDSP-like sequences in 100 control samples. These findings, together with the observation of unaltered hybridisation patterns of genomic DNA with a SBDS probe (Fig. 2d), indicated that gene conversion due to recombination between SBDS and its highly homologous pseudogene had occurred. A similar basis for mutation has been observed in other genetic diseases\(^7\text{-}19\). Sequence analysis of the exon 2 region of patients indicated that most conversion events are confined to a short segment between 141 bp and 258+124 bp with a maximum size of 240 bp (Fig. 2a, b). Based on restriction digestion or sequencing of PCR products of patients from 158 unrelated families, 74% of SDS alleles (n=235 of 316) are the result of gene conversion, with 89% of patients carrying at least one converted allele and 60% carrying two converted alleles. Consistent with being a recessive disease, patients carry mutations on both copies of the SBDS gene. Of the patients analysed in the initial study, 50% were \([183TA>CT] + [258+2T>C]\) compound heterozygotes, 5.1% were \([183TA>CT + 258+2T>C] + [258+2T>C]\) compound heterozygotes, and 4.4% were homozygous for a \([258+2T>C]\) conversion. Of patient alleles not displaying the conversion mutations, genomic sequencing revealed other changes within the coding region of SBDS, including small deletions, insertions, and nucleotide substitutions that would lead to frameshift and premature truncation, missense and nonsense changes (Table 1 and Fig. 4). To date, these mutations were not detected in 100 Caucasian control DNA samples by allele specific oligonucleotide hybridization or correspond to changes of highly conserved amino acids that would not be expected to be important for protein structure or function. Table 1 shows the SDS-associated mutations identified in the initial study and in subsequent studies.
Example 2

RNA hybridisation with SBDS indicated broad expression of a 1.6 kb message (Fig. 3a). Numerous GenBank EST clones, however, indicated that the pseudogene is also transcribed. Prominent larger-sized transcripts were also observed in poly(A)+ mRNA from several tissues and were confirmed to include intron 1 through hybridisation of an intron 1-specific probe (Fig. 3a). In addition, three GenBank EST clones corresponding to SBDSP were found to contain intron 1.

RNA expression analysis was carried out on a number of normal adult or fetal tissues, and on lymphoblasts from a number of SDS patients. As seen from Figure 3b, the level of combined SBDS/SBSDP mRNA, and consequently of protein product, was notably reduced in patient samples, compared with control C, lymphoblast RNA from a healthy subject.

Distinction between expression of the gene and pseudogene could be obtained through RT-PCR with specific oligonucleotide primers (Fig. 3c). Further, a broad survey of tissues revealed that the majority of SBDS mRNA does contain exon 2 although its alternative splicing was prominent in some patients (Fig. 3c and data not shown). Both RT-PCR and RNA analyses supported widespread expression of SBDS in all tissues examined, including the most disease-relevant tissues, pancreas, bone marrow, and myeloid lineages (Fig. 3a, c).

Example 3

Generation of antibodies for SBDS protein detection

Two methods were used to generate specific antibody probes to detect SBDS protein cells and tissues. First, a bacterially expressed polypeptide with the entire open reading frame of SBDS and, second, specified peptides synthesised from the amino and carboxyl portion (see legend to Fig. 7), were used as immunogens in rabbits. To obtain high level expression of recombinant SBDS, the complete open reading frame of the SBDS gene was incorporated into the pET28a vector (Novagen) using standard molecular biology techniques (Ref. 30). The open reading frame was fused with the
(HIS)_6 tag of the expression vector for purification with immobilised metal (Ni^{2+}) affinity chromatography. The purified polypeptide was then conjugated and injected into rabbits with the services of Washington Biotechnology, Inc. Pre-immune and immune sera were collected and whole cell protein extracts of various cell types were assessed, Fig. 7. The amino and carboxyl peptide antibodies were synthesised and prepared with the services of AnaSpec, Inc. and Washington Biotechnology, Inc., respectively. The antibodies showed high affinity and specificity for the SBDS protein product in different organs and cell lines, by Western blotting carried out as follows.

Whole cell extracts were prepared with Laemmli (E. coli) or RIPA (mammalian cells) buffer (and separated by 13.5% PAGE prior to blotting on Hybond C Extra (Amersham) membrane (Ref. 30 and Harlow and Lane). For rSBDS and anti-CpSBDS anti-sera, the membrane was blocked with 7% skim milk in TBST (10mM TrisHCl, pH7.3, 100mM NaCl with 0.1% Tween 20) for overnight at room temperature followed by incubation of a 1:2000 dilution for 5 h at room temperature. The blot was washed with TBST for five consecutive washes and incubated with anti-rabbit secondary antibody (Stressgen Biotechnologies Corp). The anti-Myc (Oncogene Research Products) and anti-HA (BAbCO-Covance) monoclonal antibodies and the anti-mouse secondary antibodies (Jackson ImmunoResearch Labs, Inc.) were used as recommended by their suppliers. The immunoreactive bands were detected by enhanced chemiluminescence.
Table 1: SDS-associated mutations

<table>
<thead>
<tr>
<th>Nucleotide Sequence Changes</th>
<th>Predicted Amino Acid Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>183_184TA→CT</td>
<td>K62X</td>
</tr>
<tr>
<td>183_184TA→CT+258+2T→C</td>
<td>K62X</td>
</tr>
<tr>
<td>258+2T→C</td>
<td>84Cfs3</td>
</tr>
<tr>
<td>24C→A</td>
<td>N8K</td>
</tr>
<tr>
<td>96-97insA</td>
<td>N34fs15</td>
</tr>
<tr>
<td>119delG</td>
<td>S41fs17</td>
</tr>
<tr>
<td>131A→G</td>
<td>E44G</td>
</tr>
<tr>
<td>199A→G</td>
<td>K87E</td>
</tr>
<tr>
<td>258+1G→C</td>
<td>84Cfs3</td>
</tr>
<tr>
<td>260T→G</td>
<td>I87S</td>
</tr>
<tr>
<td>291-293delTAAlinsAGTTCAAGTATC</td>
<td>D97-K98delinsEVQVS</td>
</tr>
<tr>
<td>377G→C</td>
<td>R126T</td>
</tr>
<tr>
<td>505C→T</td>
<td>R169C</td>
</tr>
<tr>
<td>56G→A</td>
<td>R19Q</td>
</tr>
<tr>
<td>93C→G</td>
<td>C31W</td>
</tr>
<tr>
<td>97A→G</td>
<td>K33E</td>
</tr>
<tr>
<td>101A→T</td>
<td>N34I</td>
</tr>
<tr>
<td>123delC</td>
<td>S41fs17</td>
</tr>
<tr>
<td>279_284delTCAACT</td>
<td>Q94_V95del</td>
</tr>
<tr>
<td>296_299delAAGA</td>
<td>E99fs20</td>
</tr>
<tr>
<td>354A→C</td>
<td>K118N</td>
</tr>
<tr>
<td>428C→T+443A→G</td>
<td>S143L + K148R</td>
</tr>
<tr>
<td>458A→G</td>
<td>Q153R</td>
</tr>
<tr>
<td>460-1G→A</td>
<td>splice</td>
</tr>
<tr>
<td>506G→C</td>
<td>R169P</td>
</tr>
<tr>
<td>624+1G→C</td>
<td>splice</td>
</tr>
</tbody>
</table>
Table 2: *SBDS Polymorphisms*

Some sequence changes in *SBDS* are predicted to be silent polymorphisms. Although some of these changes were detected in SDS patients, allele-specific oligonucleotide hybridisation was used to screen control samples to determine that these changes are not disease associated and should be classified as silent polymorphisms.

<table>
<thead>
<tr>
<th>Nucleotide Sequence Change</th>
<th>Predicted Amino Acid Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intron 1</strong></td>
<td></td>
</tr>
<tr>
<td>129-71G→A</td>
<td></td>
</tr>
<tr>
<td>129-185G→A</td>
<td></td>
</tr>
<tr>
<td>129-225C→G</td>
<td></td>
</tr>
<tr>
<td>129-265G→A</td>
<td></td>
</tr>
<tr>
<td><strong>Intron 2</strong></td>
<td></td>
</tr>
<tr>
<td>258+19A→G</td>
<td></td>
</tr>
<tr>
<td>258+54T→G</td>
<td></td>
</tr>
<tr>
<td>258+99A→C</td>
<td></td>
</tr>
<tr>
<td><strong>Intron 3</strong></td>
<td></td>
</tr>
<tr>
<td>459+92A→G</td>
<td></td>
</tr>
<tr>
<td><strong>Exon 2</strong></td>
<td></td>
</tr>
<tr>
<td>141C→T</td>
<td>L47L</td>
</tr>
<tr>
<td>201A→G</td>
<td>K67K</td>
</tr>
<tr>
<td><strong>Exon 5</strong></td>
<td></td>
</tr>
<tr>
<td>651C→T</td>
<td>F217F</td>
</tr>
<tr>
<td>635T→C</td>
<td>I212T</td>
</tr>
<tr>
<td><strong>Rare Change</strong></td>
<td></td>
</tr>
<tr>
<td>210T→C</td>
<td>D70E</td>
</tr>
</tbody>
</table>
The common mutations that account for the majority of SDS alleles can be detected by a PCR-restriction enzyme digestions of Bsu36I and Cac8I. These digestions can be performed singly (as described on page 27, methods) or in combination as detailed below. The combination digestion permits distinction between the conversions encompassing

**PCR Amplification (same as for single digests already described)**

Primer E (SEQ ID NO: 7): 5' –AAATGGAAGCAAATACGG- 3'
Primer F (SEQ ID NO: 8): 5' –ACCAAGTCTTTATTAGAAGTGAC- 3'

product size: 733 bp
annealing temperature: 56.6 C
extension time: 40 sec

**Double Digestion**

*Bsu36 I* (New England Biolabs #R0524): 6 units plus
*Cac8 I*  (New England Biolabs #R0579): 4.8 units
per 100-200ng PCR product
Digest 37 C >3hr

**Band Sizes detected on agarose gel with ethidium bromide intercalation**

Normal: 584bp also 64bp, 41bp, and smaller bands that are difficult to see
258+2 T>C: 431bp and 153bp also 64bp, 41bp and smaller bands
183 TA>CT: 358bp and 226bp also 64 bp, 41 bp and smaller bands
258+2T>C + 183TA>CT: 358bp, 153bp, 73bp also 64bp, 41bp and smaller bands

Note: Cannot use *DdeI* for this double digest, must use *Bsu36I* and *Cac8I*.

Mouse and human gene
88% nucleotide identity
97% amino acid identity
Dual Specific Digests for Common Mutations

PCR Amplification

Forward Primer: 5’ – GGGGATTTGTTGTTGTCTT - 3’
Reverse Primer: 5’ – CTTTCCTCCAGAAAAACAGC - 3’

product size: 336 bp
annealing temperature: 56 °C
extension time: 1 min

Cae8 I Digest

Cae8 I (NEB #R0579): 4.8 units
Digest 37 °C >3hr

Band Size
Normal: 2 X 336 bp, 2 X 241 bp, 2 X 95 bp
1 allele with 258+2 T>C: 1 X 336 bp, 3 X 241 bp, 3 X 95 bp
2 alleles with 258+2 T>C: 4 X 241 bp, 4 X 95 bp

Dde I Digest

Dde I (NEB #R0175): 6 units
Digest 37 °C 2hr

Band Size
Normal: 2 X 190 bp, 2 X 169 bp, 4 X 146, 2 X 21 bp
1 allele with 183 TA>CT: 1 X 190 bp, 3 X 169 bp, 4 X 146, 2 X 21 bp
2 alleles with 183 TA>CT: 4 X 169 bp, 4 X 146, 2 X 21 bp
References


We Claim:

1. A method for determining whether a subject is suffering from Schwachman-Diamond Syndrome (SDS) comprising
   obtaining a nucleic acid sample from the subject, and
   conducting an assay on the nucleic acid sample to determine the presence or absence of a SBDS gene mutation associated with SDS, wherein the presence of a SBDS gene mutation associated with SDS in both SBDS alleles indicates that the subject suffers from SDS.

2. The method of claim 1 wherein the assay is selected from the group consisting of probe hybridisation, direct sequencing, restriction enzyme fragment analysis and fragment electrophoretic mobility.

3. The method of claim 2 wherein the nucleic acid sample is a DNA sample or an RNA sample and the assay is a direct sequencing assay.

4. The method of claim 3 wherein the nucleic acid sample is a genomic DNA sample and the assay comprises the steps of:
   (a) amplifying a target portion of the nucleotide sequence of the genomic DNA;
   (b) obtaining the nucleotide sequence of said amplified target portion; and
   (c) determining the presence or absence of a SBDS gene mutation associated with SDS in said target portion of the nucleotide sequence.

5. The method of claim 3 wherein the nucleic acid sample is an RNA sample and the assay comprises the steps of:
   (a) reverse transcribing the RNA sample to produce a corresponding cDNA;
(b) performing at least one polymerase chain reaction with suitable oligonucleotide primers to amplify the SBDS cDNA;
(c) obtaining the nucleotide sequence of the amplified SBDS cDNA; and
(d) determining the presence or absence of a SBDS gene mutation associated with SDS in said nucleotide sequence.

6. The method of claim 4 or 5 wherein the presence or absence of a mutation selected from the group consisting of 24C>A; 97_97insA; 119delG; 131A>G; 183TA>CT; 183TA>CT + 201A>G+258+2T>C; 199A>G; 258+2T>C; 258+1G>C; 260T>G; 291_293delTAinsAGTTCAAGTATC; 377G>C; 505C>T+651C>T, 183_184TA CT; 183_184TA CT+258+2T C; 258+2T C; 24C A; 96-97insA; 119delG; 131A G; 199A G; 258+1G C; 260T G; 291-293delTAinsAGTTCAAGTATC; 377G C; 505C T; 56G A; 93C G; 97A G; 101A T; 123delC; 279_284delTCAACT; 296_299delAAGA; 354A C; 428C T+443A G; 458A G; 460-1G A; 506G C; and 624+1G C is determined.

7. The method of claim 4 or 6 wherein the target portion of the nucleotide sequence is amplified using a primer pair selected from the group consisting of:

(a) Primer A and Primer B;
(b) Primer E and Primer F;
(c) Primer G and Primer H;
(d) Primer SDCR9x4seqB and Primer J;
(e) Primer SDCR9x5Fseq and Primer L;
(f) Primer Q and Primer B;
(g) Primer I and Primer J;
(h) Primer K and Primer L; and
(i) Primer SDCR9prom1RA and Primer SDCR9prom6FA.

8. The method of claim 2 wherein the nucleic acid sample is a DNA sample and the assay is a restriction enzyme fragment analysis.
9. The method of claim 8 wherein the assay comprises the steps of:
   (a) digesting the DNA with a restriction enzyme to give restriction fragments;
   (b) separating the restriction fragments by agarose gel electrophoresis; and
   (c) detecting the separated fragments by hybridisation of the fragments to a detectably labelled nucleotide probe specific for SBDS.

10. The method of claim 9 wherein the restriction enzyme is at least one of Cac81 and Bsu361.

11. The method of any one of claims 1 to 10 wherein the subject is a human subject.

12. A method for determining whether a subject is an SDS carrier comprising
    obtaining a nucleic acid sample from the subject, and
    conducting an assay on the nucleic acid sample to determine the presence or absence of a SBDS gene mutation associated with SDS, wherein the presence of a SBDS gene mutation associated with SDS in one SBDS allele indicates that the subject is an SDS carrier.

13. The method of claim 12 wherein the assay is selected from the group consisting of probe hybridisation, direct sequencing, restriction enzyme fragment analysis and fragment electrophoretic mobility.

14. The method of claim 13 wherein the nucleic acid sample is a DNA sample or an RNA sample and the assay is a direct sequencing assay.
15. The method of claim 14 wherein the nucleic acid sample is a genomic DNA sample and the assay comprises the steps of:
   (a) amplifying a target portion of the nucleotide sequence of the genomic DNA;
   (b) obtaining the nucleotide sequence of said amplified target portion; and
   (c) determining the presence or absence of a SBDS gene mutation associated with SDS in said target portion of the nucleotide sequence.

16. The method of claim 14 wherein the nucleic acid sample is an RNA sample and the assay comprises the steps of:
   (a) reverse transcribing the RNA sample to produce a corresponding cDNA;
   (b) performing at least one polymerase chain reaction with suitable oligonucleotide primers to amplify the SBDS cDNA;
   (c) obtaining the nucleotide sequence of the amplified SBDS cDNA; and
   (d) determining the presence or absence of a SBDS gene mutation associated with SDS in said nucleotide sequence.

17. The method of claim 15 or 16 wherein the presence or absence of a mutation selected from the group consisting of 24C>A; 97_97insA; 119delG; 131A>G; 183TA>CT; 183TA>CT + 201A>G+258+2T>C; 199A>G; 258=2T>C; 258+1G>C; 260T>G; 291_293delTAAlnsAGTTCAAGTATC; 377G>C; 505C>T+651C>T; 183_184TA CT; 183_184TA CT+258+2T C; 258+2T C; 24C A; 96-97insA; 119delG; 131A G; 199A G; 258+1G C; 260T G; 291-293delTAAlnsAGTTCAAGTATC; 377G C; 505C T; 56G A; 93C G; 97A G; 101A T; 123delC; 279_284delTCAACT; 296_299delAAGA; 354A C; 428C T+443A G; 458A G; 460-1G A; 506G C; and 624+1G C is determined.
18. The method of claim 15 or 16 wherein the target portion of the nucleotidesequence is amplified using a primer pair selected from the group consisting of:

(a) Primer A and Primer B;
(b) Primer E and Primer F;
(c) Primer G and Primer H;
(d) Primer SDCR9x4seqB and Primer J;
(e) Primer SDCR9x5Fseq and Primer L;
(f) Primer Q and Primer B;
(g) Primer I and Primer J;
(h) Primer K and Primer L; and
(i) Primer SDCR9prom1RA and Primer SDCR9prom6FA.

19. The method of claim 13 wherein the nucleic acid sample is a DNA sample and the assay is a restriction enzyme fragment analysis.

20. The method of claim 19 wherein the assay comprises the steps of:

(a) digesting the DNA with a restriction enzyme to give restriction fragments;
(b) separating the restriction fragments by agarose gel electrophoresis; and
(c) detecting the separated fragments by hybridisation of the fragments to a detectably labelled nucleotide probe specific for SBDS.

21. The method of claim 20 wherein the restriction enzyme is Nde 1.

22. The method of any one of claims 12 to 21 wherein the subject is a human subject.

23. A method for determining whether a subject is suffering from Shwachman-Diamond Syndrome (SDS) comprising
obtaining a tissue sample from the subject, and
conducting an assay on the tissue sample to determine the level of
SBDS protein in the sample, wherein a reduced level of SBDS protein in the
sample relative to a control sample indicates that the subject suffers from
SDS.

24. The method of claim 23 wherein the tissue sample is selected from the
group consisting of blood, buccal smear or bone marrow aspirate.

25. A method for determining whether a subject is at risk for developing
acute myelogenous leukaemia (AML) comprising
obtaining a nucleic acid sample from the subject, and
conducting an assay on the nucleic acid sample to determine the
presence or absence of a SBDS gene mutation associated with SDS, wherein
the presence of a SBDS gene mutation associated with SDS indicates that
the subject is at risk for development of AML.

26. A method for treating a subject suffering from SDS comprising
administering to the subject a therapeutically effective amount of a
substantially purified SBDS protein or of an isolated nucleotide sequence
encoding an SBDS protein.

27. The method of claim 26 wherein a sample of bone marrow cells is
obtained from the subject and the bone marrow cells are transfected with a
nucleotide sequence encoding an SBDS protein and re-introduced into the
subject.

28. The method of claim 26 or 27 wherein the nucleotide sequence
encodes a protein of amino acid sequence SEQ ID NO:2.

29. The method of claim 26 or 27 wherein the nucleotide sequence is the
sequence of SEQ ID NO:1.
30. The method of claim 26 wherein the substantially purified SBDS protein has the amino acid sequence of SEQ ID NO:2.

31. An isolated nucleic acid molecule encoding an SBDS protein.

32. The nucleic acid molecule of claim 31 wherein the protein is a human SBDS protein.

33. The nucleic acid molecule of claim 32 comprising a nucleotide sequence selected from the group consisting of:
   (a) the nucleotide sequence of SEQ ID NO:1;
   (b) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:2;
   (c) a nucleotide sequence which is a complement of a nucleotide sequence of (a) or (b); and
   (d) a nucleotide sequence which hybridises under stringent conditions to a nucleotide sequence of (a) or (b).

34. The nucleic acid molecule of claim 31 wherein the protein is a murine SBDS protein.

35. The nucleic acid molecule of claim 34 comprising a nucleotide sequence which encodes the amino acid sequence of SEQ ID NO:29 or comprising the nucleotide sequence of SEQ ID NO:29.

36. The nucleic acid molecule of claim 34 wherein the nucleotide sequence has at least one mutation selected from the group consisting of 24C>A; 97_97insA; 119delG; 131A>G; 183TA>CT; 183TA>CT+
201A>G+258+2T>C; 199A>G; 258+2T>C; 258+1G>C; 260T>G;
291_293delTAAinsAGTTCAAGTATC; 377G>C; 505C>T+651C>T,
183_184TA CT; 183_184TA CT+258+2T C; 258+2T C; 24C A; 96-97insA;
119delG; 131A G; 199A G; 258+1G C; 260T G; 291-293delTAAGTCAAGTATC; 377G C; 505C T; 56G A; 93C G; 97A G; 101A T; 123delC; 279_284delTCAACT; 296_299delAAGA; 354A C; 428CT+443A G; 458A G; 460-1G A; 506G C; and 624+1G C is determined.

37. The nucleic acid molecule of any one of claims 31 to 35 wherein the molecule is a DNA molecule.

38. The nucleic acid molecule of any one of claims 31 to 35 wherein the molecule is an RNA molecule.

39. A recombinant vector comprising the isolated nucleic acid molecule of any one of claims 31 to 38.

40. A host cell comprising the vector of claim 39.

41. An isolated nucleic acid molecule comprising at least about 10, 20, 30, 50, 75 or 100 consecutive nucleotides of SEQ ID NO:1 or 29.

42. A substantially purified SBDS protein.

43. The protein of claim 42 comprising an amino acid sequence selected from the group consisting of:
   (a) the amino acid sequence of SEQ ID NO:2;
   (b) the amino acid sequence of SEQ ID NO:29.

44. An antibody which binds specifically to an epitope of an SDS protein.

45. The antibody of claim 44 wherein the antibody binds specifically to an SBDS protein having at least 89% amino acid identity with a protein comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:29.
46. A hybridoma cell line which produces an antibody in accordance with claim 44 or 45.

47. A method for preparing an SBDS protein comprising expressing the nucleotide sequence of any one of claims 31 to 38 in a suitable expression system and collecting the expressed protein.

48. A nucleotide sequence selected from the group consisting of:
   (a) 5'-GCCTAAAAAGCCACAATAAC-3' (SEQ ID NO:3);
   (b) 5'-CTATGACAGTATTCGTAAGACTAGG-3' (SEQ ID NO:4);
   (c) 5'-GGGGATTGTTGTTGCTCTG-3' (SEQ ID NO:5);
   (d) 5'-CTTTCCTCCACAGAAACACAGC-3' (SEQ ID NO:6);
   (e) 5'-AAATGGAAGGCAAATACGG-3' (SEQ ID NO:7);
   (f) 5'-ACCAAGTTTCTTATTATTAGAAGTGAC-3' (SEQ ID NO:8);
   (g) 5'-GCTCAAAACATTACCTATTTGA-3' (SEQ ID NO:9);
   (h) 5'-CCTTGCTTCCCATGCAGA-3' (SEQ ID NO:10);
   (i) 5'-AAAGGTCATTAAAAACACTTC-3' (SEQ ID NO:11);
   (j) 5'-GAAATATCTGACGTCTTCAAACA-3' (SEQ ID NO:12);
   (k) 5'-TCCACTGTAGATGTGAACCTACTC-3' (SEQ ID NO:13);
   (l) 5'-CCTCTGGACTTTTCATCT-3' (SEQ ID NO:14);
   (m) 5'-CCTTTCCACTCCAG-3' (SEQ ID NO:15);
   (n) 5'-AGCTATGCTGCAGCTTAC-3' (SEQ ID NO:16);
   (o) 5'-ATGCATGTCGAAATTTGGAAG-3' (SEQ ID NO:17);
   (p) 5'-TCCATGGTATATTTGTGTA-3' (SEQ ID NO:18);
   (q) 5'-TAAGCTCGCCAGACAC-3' (SEQ ID NO:19);
   (r) 5'-CCTCTGGACTTTGTACCT-3' (SEQ ID NO:20);
   (s) 5'-TGTTGGGTGTTACCAAGAATA-3' (SEQ ID NO:21);
   (t) 5'-AGATAAGAAGACACACACAC-3' (SEQ ID NO:22);
   (u) 5'-GAAATCGCTGCTACAAAA-3' (SEQ ID NO:23);
   (v) 5'-TCAGCTTTCTGCCTTCAT-3' (SEQ ID NO:24);
   (w) 5'-TAAGTAAGCCTGCCAGACA-3' (SEQ ID NO:25);
   (x) 5'-CATCAAGGTTCTTTTCAAG-3' (SEQ ID NO:26);
(y) 5'-CCTGTCCTCTGCCCAGTC-3' (SEQ ID NO:27); and
(z) 5'-AGGGAACATTTCTAAAACCTCA-3' (SEQ ID NO:28).

49. A transgenic non-human mammal having within its genome an SBDS gene with at least one mutation associated with SDS.

50. The mammal of claim 49 wherein the mammal is selected from the group consisting of mice, rats, rabbits, sheep, goats and non-human primates.

51. The mammal of claim 49 wherein the mammal is a mouse.

52. A kit comprising at least one pair of primers suitable for amplification of at least a portion of an SBDS gene.
FIGURE 2
Figure 3

(a) adult tissues
(b) fetal tissues
(c) immune system
(d) SDS patient lymphoblasts

711 bp
328 bp
479 bp
349 bp
983 bp
SBDS cDNA Sequence ID NO:1

-184 gtgaatgcgc ctgacagaca cactgtcgtg cgtgcctgaa gctagtctagc gcgcgcccgc
-124 gcagtctgtg gtggtggcct gtagcgcgcgc cgatcgcgtg ttaccgcggag gcgcgcgtgtg
-64 ctctcagcct ggcgctggcg gttgacgcttc gttccgctgg cttctgggttc ttggagacgc
-4 cggcgtgtgct acctgagcacc cacaacacacacacacagcc gaattcagctagaactacag
+57 gatgagacgt ccgggagagc cgtcctcacaagc gttgcctgct acggcctgcaccg aaaaagagag cggtgctgcctg
+117 gcggagcggcc gccggaagac ccctctagtg aacaagatcag agttcctgaga cggcctggag agttcctgcctg
+177 tgttggctaaa gcggaggtgtc ccgaaagcgc agatacctagc tactccactcc ccctctcttt ctctctctctt
+237 ccaagctgaa tccggagagt gaaaattagc ggtggagggc gcgttcggagag cggcctggagag cggcctggagag
+297 aagacacaca caactgagcag agatgttttag ggcactttgcca actattggag ccagaacattt
+357 tgtcagactc cagcattgaag caccacacacacacacac ccgtgagcaacagtctgagag cagcattgagac
+417 catccctcat tcggtggtcc cacaacgcag cagcattgag tccgggacag cggcctttgag cagcattgagc
+477 gcgcgtgctg ttctgagcc gatgtgagtg cgcggagcag cgcggagcag cggcctttgag cagcattgagc
+537 agtgaatcct ggggaagagag ccgagagaga cgctgagcag cggcctttgag cagcattgagc
+597 tcatcctatt tcggtggtcc cacaacgcag cagcattgag tccgggacag cggcctttgag cagcattgagc
+657 aaatatcatt cctatgaggg ggtgtagagag cggcctttgag cagcattgagc
+717 gaaagactg gaaagactg gaaagactg gaaagactg gaaagactg gaaagactg gaaagactg
+777 aagcaacta agttcctgag cttccgagcg cactgttctca tgctctgggt ctggccaaataa
+837 cttcagctata ttatagccat gcagcattta cctctctctc ctctctctctc ctctctctctc
+897 ctacatagtt atataactgt ggtgatttaa tataactgt ggtgatttaa tataactgt ggtgatttaa
+957 cttaagccaaa atataactgt taccctttct aataatcag ctctctctct ctctctctctct ctctctctctct
+1017 atcgctgctg ctttcctttc atataatctg ggtgatttaa tataactgt ggtgatttaa tataactgt ggtgatttaa
+1077 tctttgttaa atatatcgcg gcagcattta cctctctctc ctctctctctc ctctctctctc ctctctctctc
+1137 tccctaaaaa aataaatcag gcagcattta cctctctctc ctctctctctc ctctctctctc ctctctctctc
+1227 tctatacttc atatatcgcg gcagcattta cctctctctc ctctctctctc ctctctctctc ctctctctctc
+1287 tctatacttc atatatcgcg gcagcattta cctctctctc ctctctctctc ctctctctctc ctctctctctc
+1347 tctatacttc atatatcgcg gcagcattta cctctctctc ctctctctctc ctctctctctc ctctctctctc
+1497 tctatacttc atatatcgcg gcagcattta cctctctctc ctctctctctc ctctctctctc ctctctctctc
+1647 tctatacttc atatatcgcg gcagcattta cctctctctc ctctctctctc ctctctctctc ctctctctctc
+1807 tctatacttc atatatcgcg gcagcattta cctctctctc ctctctctctc ctctctctctc ctctctctctc
+1957 tctatacttc atatatcgcg gcagcattta cctctctctc ctctctctctc ctctctctctc ctctctctctc
+2107 tctatacttc atatatcgcg gcagcattta cctctctctc ctctctctctc ctctctctctc ctctctctctc
+2257 tctatacttc atatatcgcg gcagcattta cctctctctc ctctctctctc ctctctctctc ctctctctctc

SBDS Amino Acid Sequence ID NO:2

1 MSIPPTPtQI RLNVAVVCRM KRAKGRKFSIA CYKNKVVGWR SGVEKDLDEV LQTHSVPFNV
61 SKQVAKEDERALISAFDPDQOETRQQQLTGRHVGFHESKHRHTQLSEQMDITATIAKCY
121 NPBRKRYTVI ILIERAKMOI HYSVKGVST SQQALEVIEQ LKERMKIHEA HMLRFLIDPV
181 NEQXKLKERK KPLIKIVFSE YDGQQLEIVC LDLPGCFRBI DLELLKETGKG KSLLEVLNLK
241 DVSEGDIEKPE

Figure 5
MUSD5: tttaggccctgtgaatccccacgccccaggaactgaggccaggagattggctgccagtttccag

SBDS: ggtgtcataaaaagctgcagcccaaagaaatctgtaaatgttgtgctcttttccctagaataatg
SBDSP: ggtgtcataaaaagctgcagcccaaagaaatctgtaaatgttgtgctcttttccctagaataatg
MUSD5: gccaagccctggaaagctgtgtgtgtgtgtgtatgtgtgtgtgtgtgtgtgtgtgtgtatgtgt

← Primer B (SDCR9x1BR)
SBDS: atggctgagaacctagtctttacgaatactgtcatag
SBDSP: atggctgagaacctagtctttacgaatactgtcatag
MUSD5: atgtgtgtgtgtagagagacccgtgaccgcacctgtac

SBDS Exon 2:
Primer E (SDCR9x2BF) →
SBDS: aaatgtaagggcaaaatagcctctgtgattttggaaatgttcctcagggccgtgggca
SBDSP: aaatgtaagggcaaaatagcctctgtgattttggaaatgttcctcagggccgtgggca
MUSD5: gtaatgtcttcgctactgcaatctagggacagatattccaggacagaaacaccactc

SBDS: gttcacttgagggccagggagttcaggggcagctgctggccaaatggaaccactctcttacta
SBDSP: gatcaacttgagggccagggagttcaggggcagctgctggccaaatggaaccactctcttacta
MUSD5: cccaccacacccctgagttttccctacataaaacaatgatcggtgtattttcccctctggtgta

SBDS: aaaaataacaaagttagcccggttgtgtggtggtgggcgtgcctgtaatcccaaggttaactcaggagc
SBDSP: aaaaataacaaagttagcccggttgtgtggtggtgggcgtgcctgtaatcccaaggttaactcaggagc
MUSD5: agtgaggagatccacagatactgtctttgaggtagccaccagagagagtgtgtgtgtgt

SBDS: tgagccggagagatccctagaaaccggaggctgagttcagttgacccagagatccgcgc
SBDSP: tgagccggagagatccctagaaaccggaggctgagttcagttgacccagagatccgcgc
MUSD5: gtctgtgtgtgagatcttttttttttttttttttttttttttttttttttttttttttttttttttttttt
SBDS  tacattatggaacttggttttgtgagggtcattatatgtatcgtaatgttaagctttggtatga
SBDSP  tacattatggaacttggttttgtgagggtcattatatgtatcgtaatgttaagctttggtatga
MUSBSDS  ccaatagattttataatgacagggggaatggacttttctaaatattttcaaccaacatgctac

SBDS  tggctctgattatatctgagaaacagatataagaaaaatttggtgccggac-ac---taccttttca
SBDSP  tggctctgattatatctgagaaacagatataagaaaaatttggtgcggactttaaataatatttccg
MUSBSDS  ccaaaactgacattgtttctgggaaatatataacagtcatttaataactaatctttaa

SBDS  ttgaaacatgtgtccataacttagattatctttggttaaaaaatatggtttaagttcactttattttct
SBDSP  ttgaaacatgtgtccataacttagattatctttggttaaaaaatatggtttaagttcactttattttct
MUSBSDS  agttttataataatatgattagttatagtttaaaaactctagttgtatcaatcaataaaacttattttta

(site)

SBDS  aattcttaaagttttataatatattatatagctaaaatttgtatgtatcaataaaaaacc
SBDSP  aattcttaaagttttataatatattatatagctaaaatttgtatgtatcaataaaaaacc
MUSBS  c

(end of human transcript, mRNA of 1605nt)

SBDS  aacctttatgtttttattaaactatggtttgtttctagacaacaccttcttacctttttctttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt
Figure 7
### Classification of Subject Matter

**IPC 7**  
C12Q/68  
C07K14/47  
C07K16/18

According to International Patent Classification (IPC) or to both national classification and IPC.

### Fields searched

Minimum documentation searched (classification system followed by classification symbols)

**IPC 7**  
C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (name of database and, where practical, search terms used)

EPO-Internal, SEQUENCE SEARCH, WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE, CHEMABS Data, EMBL

### Documents Considered to be Relevant

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>
| X        | EP 1 074 617 A (HELIx RES INST)  
7 February 2001 (2001-02-07)  
* see especially SEQ ID NO:12429,  
reflected by gene accession number  
AAH14710  
abstract; claims 8-15  
& DATABASE EMBL 'Online!  
26 June 2001 (2001-06-26)  
OTA T ET AL.: "Human cDNA sequence SEQ ID  
NO:12429"  
retrieved from EMBL  
Database accession no. AAH14710  
abstract | 31-33,  
35,37-47 |

Further documents are listed in the continuation of box C.

<table>
<thead>
<tr>
<th>X</th>
<th></th>
</tr>
</thead>
</table>

**X** Patent family members are listed in annex.

* Special categories of cited documents:

A* document defining the general state of the art which is not considered to be of particular relevance.

E* earlier document but published on or after the international filing date.

L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation of other special reason (as specified).

O* document referring to an oral disclosure, use, exhibition or other means.

P* document published prior to the international filing date but later than the priority date claimed.

**T** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.

**X** document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone.

**Y** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

**&** document member of the same patent family.

Date of the actual completion of the international search

4 February 2004

Date of mailing of the international search report

19/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL – 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Knehr, M

Form PCT/ISA/210 (second sheet) (July 1992)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>DATABASE GENBANK ‘Online!’ Accession number AK001779, 22 February 2000 (2000-02-22) ISOGAI T AND OTSUKI T: &quot;NEDO human cDNA sequencing project&quot; XP002268960 abstract</td>
<td>31-33, 35,37-47</td>
</tr>
</tbody>
</table>
INTERNATIONAL SEARCH REPORT

Box I  Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. **X** Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
   
   see FURTHER INFORMATION sheet PCT/ISA/210

2. **X** Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
   
   see FURTHER INFORMATION sheet PCT/ISA/210

3. **☐** Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II  Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. **☐** As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. **☐** As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. **☐** As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. **☐** No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- **☐** The additional search fees were accompanied by the applicant's protest.
- **☐** No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)
Continuation of Box I.1

Although claims 1-25 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Although claims 26-30 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.2

Sequence ID NOS disclosed within claims 7, 18, and 48, referring to SEQ ID NOS:3-28, and 32-35, were interpreted as to be SEQ ID NOS:4-29, and 33-36 (as compared with the sequence listing with letter from 16.12.2003).

Present claims 31, 42, 44, 46, 47, and 49-52, relate to products and a method defined by reference to a desirable characteristic or property, namely...
- a nucleic acid molecule encoding and SBDS protein (claim 31),
- an SBDS protein (claim 42),
- an antibody binding specifically to an epitope of an SDS protein (claim 44),
- a hybridoma cell line producing such an antibody (claim 46),
- a method for preparing an SDS protein by expressing its nucleotide sequence in a suitable expression system (claim 47),
- a transgenic non-human animal comprising in its genome a mutated SBDS gene (claims 49-51), and
- a kit comprising a pair of primers suitable for amplifying a part of a SBDS gene (claim 52).

The claims cover all products or a method having these characteristics or properties, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products and method. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the products and method by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.
Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the products of claims 31, 42, 44, 46, and 49-52, relating to SEQ ID NOS:1-29, as claimed, as well as a method of expression (claim 47), also relying on the SEQ ID NOS:1-29.

Evidence of disposal of the cell line as claimed within claim 46, must be provided.

Present claims 35, 41, 43 and 45 relate to SEQ ID NO:29 which should represent an encoding amino acid sequence, but in fact does represent a
short oligonucleotide/primer sequence (see sequence listing). Since it is not apparent which SEQ ID NO is meant instead, consequently the (parts of the) claims 35, 41, 43 and 45, referring to SEQ ID NO:29, lack conciseness within the meaning of Article 6 PCT to such an extent as to render a meaningful search of these (parts of the) claims impossible. Furthermore, it is assumed that the first part of claim 35 refers to SEQ ID NO:2, likewise to claims 43 or 45. Thus, the search of claims 35, 41, 43 and 45 was limited to SEQ ID NO:1 or 2, respectively.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>AU 6180900 A</td>
<td>19-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 6181000 A</td>
<td>19-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 6181100 A</td>
<td>19-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 6181200 A</td>
<td>19-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 6181300 A</td>
<td>19-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 6181400 A</td>
<td>19-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 6181500 A</td>
<td>19-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 6181600 A</td>
<td>19-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 6315800 A</td>
<td>19-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2380472 A1</td>
<td>08-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1074617 A2</td>
<td>07-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0109315 A1</td>
<td>08-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0109345 A1</td>
<td>08-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0109316 A1</td>
<td>08-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0109349 A1</td>
<td>08-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0109317 A1</td>
<td>08-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0109318 A1</td>
<td>08-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0109319 A1</td>
<td>08-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0109346 A1</td>
<td>08-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0109320 A1</td>
<td>08-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0109321 A1</td>
<td>08-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0109322 A1</td>
<td>08-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0109323 A1</td>
<td>08-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2002171977 A</td>
<td>18-06-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2002191363 A</td>
<td>09-07-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003157569 A1</td>
<td>21-08-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003082776 A1</td>
<td>03-05-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003017480 A1</td>
<td>23-01-2003</td>
</tr>
</tbody>
</table>